Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | ERN1 | O75460 | 6/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22530401 | 0.90 | ALOX15 (0.51) | NOTUMALDH1A1ERN1HTTALOX15 | |
| SCHEMBL1174813 | 0.86 | ALDH1A1 (0.53) | NOTUMALDH1A1ERN1HTTALOX15 | |
| SCHEMBL15715947 | 0.85 | NOTUM (0.54) | NOTUMALDH1A1ERN1HTTALOX15 | |
| SCHEMBL17747083 | 0.84 | ALDH1A1 (0.58) | ALDH1A1ERN1HTTALOX15HCRTR1 | |
| SCHEMBL15786243 | 0.83 | ALDH1A1 (0.53) | ALDH1A1ERN1HTTALOX15HCRTR1 | |
| SCHEMBL2989137 | 0.82 | CA12 (0.53) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL22530239 | 0.82 | KDM4E (0.52) | NOTUMALDH1A1HTTALOX15CA12 | |
| SCHEMBL30011802 | 0.82 | KDM4E (0.52) | NOTUMALDH1A1HTTALOX15CA12 | |
| SCHEMBL4808901 | 0.82 | CA12 (0.43) | NOTUMALDH1A1ERN1ALOX15CA12 | |
| SCHEMBL1134257 | 0.81 | L3MBTL1 (0.51) | ALDH1A1ERN1HTTHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680608-A1 | 2,6-DIHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE DERIVATIVES AS ANTI-MALARIAL AGENTS | MMV Medicines for Malaria Venture (CH) | 2026-01-21 | — | — | EP | disclosed |
| EP-4081521-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2025-12-10 | — | — | EP | disclosed |
| US-20250368667-A1 | USP1 INHIBITOR | SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD (CN) | 2025-12-04 | — | — | US | disclosed |
| US-12472271-B2 | HDAC6 inhibitors and imaging agents | THE GENERAL HOSPITAL CORPORATION (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250263405-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | VALO HEALTH, INC. | 2025-08-21 | — | — | US | disclosed |
| EP-4582427-A1 | USP1 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2025-07-09 | — | — | EP | disclosed |
| CN-119497713-A | USP1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-119462554-A | HDAC inhibitor and preparation and application thereof | 赛岚(杭州)生物医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4426285-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | Valo Health, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4397656-A2 | HDAC6 INHIBITORS AND IMAGING AGENTS | The General Hospital Corporation (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-2431367-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120046338-A1 | FUSED CYCLIC COMPOUNDS | YASUMA TSUNEO (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2041123-B1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-8088821-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| EP-2248812-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2041123-A2 | FUSED CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008001931-A2 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | NOTUM 2044/4885ALDH1A1 3122/4885ERN1 2727/4885 |
| US-20250368667-A1 | USP1 INHIBITOR | USP1, USP2, USP28 | NOTUM 3172/4885ALDH1A1 644/4885ERN1 289/4885 |
| US-12472271-B2 | HDAC6 inhibitors and imaging agents | HDAC1, HDAC6, HDAC11 | NOTUM 3049/4885ALDH1A1 2488/4885ERN1 3439/4885 |
| US-20120046338-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | NOTUM 2044/4885ALDH1A1 3122/4885ERN1 2727/4885 |
| US-20250263405-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | NOTUM 2076/4885ALDH1A1 1144/4885ERN1 3084/4885 |
| US-20100197761-A1 | Fused cyclic compounds | GPR119, GLP1R, GPR65 | NOTUM 2044/4885ALDH1A1 3122/4885ERN1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.